Interaction between amyloid β-protein aggregates and membranes

Journal of Peptide Science

Volumn 10, Issue 10, 2004, Pages 612-621

  Kakio, Atsuko ^a   Yano, Yoshiaki ^a   Takai, Denshi ^a   Kuroda, Yukihiro ^a   Matsumoto, Osamu ^a   Kozutsumi, Yasunori ^a,b   Matsuzaki, Katsumi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b Japan Science and Technology Agency   (Japan)

Author keywords

Aggregates; Alzheimer's disease; Amyloid protein; Lipid raft; Protein membrane interaction

Indexed keywords

AMYLOID BETA PROTEIN; BUFFER; CHOLESTEROL; DYE; GANGLIOSIDE GM1; MONOSIALOGANGLIOSIDE; SPHINGOMYELIN;

ARTICLE; BETA SHEET; BINDING AFFINITY; CONTROLLED STUDY; EXPERIMENTATION; FLUORESCENCE SPECTROSCOPY; HUMAN; INFRARED SPECTROSCOPY; MEMBRANE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN INTERACTION; PROTEIN STRUCTURE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; CHOLESTEROL; DIMERIZATION; G(M1) GANGLIOSIDE; HUMANS; LIPOSOMES; MODELS, BIOLOGICAL; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SPHINGOMYELINS;

EID: 6944242589     PISSN: 10752617     EISSN: None     Source Type: Journal    
DOI: 10.1002/psc.570     Document Type: Article

References (58)

1. Selkoe DJ. Cell biology of the amyloid β-protein precursor and the mechanism of Alzheimer's disease. Annu. Rev. Cell Biol. 1994; 10: 373-403.
2. Harper JD, Lansbury PT Jr. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 1997; 66: 385-407.
3. Lansbury PT Jr. Structural neurology: are seeds at the root of neuronal degeneration? Neuron 1997; 19: 1151-1154.
4. Fraser PE, Nguyen JT, Inoue H, Surewicz WK, Selkoe DJ, Podlinski MB, Kirschner DA. Fibril formation by primate, rodent, and Dutch-hemorrhagic analogues of Alzheimer amyloid β-protein. Biochemistry 1992; 31: 10716-10723.
5. Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB. Amyloid β-protein fibrillogenesis. Detection of a protofibrillar intermediate. J. Biol. Chem. 1997; 272: 22 364-22 372.
6. Naiki H, Gejyo F. Kinetic analysis of amyloid fibril formation. Methods Enzymol. 1999; 309: 305-318.
7. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, McCormack R, Woffert R, Selkoe J, Lieberburg I, Schenk D. Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids. Nature 1992; 359: 325-327.
8. Jarrett JT, Lansbury Jr PT. Seeding 'one-dimensional crystallization' of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 1993; 73: 1055-1058.
9. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB. Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways. Proc. Natl Acad. Sci. USA 2003; 100 330-335.
10. Antzukin ON, Balbach JJ, Leapman RD, Rizzo NW, Reed J, Tycko R. Multiple quantum solid-state NMR indicates a parallel, not antiparallel, organization of β-sheets in Alzheimer's β-amyloid fibrils. Proc. Natl Acad. Sci. USA 2000; 97: 13 045-13 050.
11. Balbach JJ, Petkova AT, Oyler NA, Antzukin ON, Gordon DJ, Meredith SC, Tycko R. Supramolecular structure in full-length Alzheimer's β-amyloid fibrils: Evidence for a parallel β-sheet organization from solid-state nuclear magnetic resonance. Biophys. J. 2002; 83: 1205-1216.
12. Petkova AT, Ishii Y, Balbach JJ, Antzukin ON, Leapman RD, Delaglio F, Tycko R. A structural model for Alzheimer's β-amyloid fibrils based on experimental constrains from solid state NMR. Proc. Natl Acad. Sci. USA 2002; 99: 16742-16747.
13. 1-42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA 1998; 95: 6448-6453.
14. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ. Protofibrillar intermediates of amyloid β -protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 1999; 19: 8876-8884.
15. Walsh DM, Kyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligamers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416: 535-539.
16. Dahlgren KN, Manelli AM, Stine JWB, Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J. Biol. Chem. 2002; 277: 32 046-32 053.
17. Hoshi M, Sato M, Matsumoto S, Nogichi A, Yasutake K, Yoshida N, Sato K. Spherical aggregates of β-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3β. Proc. Natl Acad. Sci. USA 2003; 100: 6370-6375.
18. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glable CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300: 486-489.
19. Salomon AR, Marcinowski KJ, Friedland RP, Zagorski MG. Nicotine inhibits amyloid formation by the β-peptide. Biochemistry 1996; 35: 13 568-13 578.
20. Tomomiya T, Shoji A, Kataoka K, Suwa Y, Asano S, Kaneko H, Endo N. Inhibition of amyloid β protein aggregation and neurotoxicity by rifampicin. J. Biol. Chem. 1996; 271: 6839-6844.
21. Lowe TL, Strzelec A, Kiessling LL, Murphy RM. Structure-function relationships for inhibitors of β-amyloid toxicity containing the recognition sequence KLVFF. Biochemistry 2001; 40 7882-7889.
22. Yanagisawa K, Odaka A, Suzuki N, Ihara Y. GM1 ganglioside-bound amyloid β-protein (Aβ): a possible form of preamyloid in Alzheimer's disease. Nat. Med. 1995; 1: 1062-1066.
23. Yanagisawa K, Ihara Y. GM1 ganglioside-bound amyloid β-protein in Alzheimer's disease brain. Neurobiol. Aging 1998; 19: S65-S67.
24. Morishima-Kawashima M, Ihara Y. The presence of amyloid β-protein in the detergent-insoluble membrane compartment of neuroblastoma cells. Biochemistry 1998; 37: 15 247-15 235.
25. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997; 385: 569-572.
26. ChooSmith L-P, Garzon-Rodriguez W, Glabe CG, Surewicz WK. Acceleration of amyloid fibril formation by specific binding of Aβ-(1-40) peptide to ganglioside-containing membrane vesicles. J. Biol. Chem. 1997; 272: 22 987-22 990.
27. McLaurin J, Franklin T, Fraser PE, Chakrabartty A. Structural transitions associated with the interaction of Alzheimer β-amyloid peptides with gangliosides. J. Biol. Chem. 1998; 273: 4506-4515.
28. Kakio A, Nishimoto S, Yanagisawa K, Kozutsumi Y, Matsuzaki K. Interactions of amyloid β-protein with various gangliosides in raft-like membranes: Importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry 2002; 41: 7385-7390.
29. Koppaka V, Axelsen PH. Accelerated accumulation of amyloid β proteins on oxidatively damaged lipid membranes. Biochemistry 2000; 39: 10 011-10 016.
30. Hasegawa K, Yamaguchi I, Omata S, Gejyo F, Naiki H. Interactions between Aβ(1-42) and Aβ(1-40) in Alzheimer's β-amyloid fibril formation in vitro. Biochemistry 1999; 38: 15 514-15 521.
31. Kakio A, Nishimoto S, Yanagisawa K, Kozutsumi Y, Matsuzaki K. Cholesterol-dependent formation of GM1 ganglioside-bound amyloid β-protein, an endogenous seed for Alzheimer amyloid. J. Biol. Chem. 2001; 276: 24 985-24 990.
32. Bartlett GR. Phosphorus assay in column chromatography. J. Biol. Chem. 1959; 234: 466-468.
33. Surewicz WK, Mantsch HH. The conformation of dynorphin A-(1-13) in aqueous solution as studied by Fourier transform infrared spectroscopy. J. Mol. Struct. 1989; 214: 143-147.
34. Kaneko I, Tutumi S. Replies to the editor. J. Neurochem. 1997; 68: 438-439.
35. Goormaghtigh E, Raussens V, Ruysschaert J-M. Attenuated total reflection infrared spectroscopy of proteins and lipids in biological membranes. Biochim. Biophys. Acta 1999; 1422: 105-185.
36. Stine JWB, Dahlgren KN, Krafft GA, LaDu MJ. In vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis. J. Biol. Chem. 2003; 278: 11 612-11 622.
37. Kakio A, Nishimoto S, Kozutsumi Y, Matsuzaki K. Formation of a membrane-active form of amyloid β-protein in raft-like membranes. Biochem. Biophys. Res. Commun. 2003; 303: 514-518.
38. Esler WP, Stimson ER, Jennings JM, Vinters HV, Ghilardi JR, Lee JP, Mantyh PW, Maggio JE. Alzheimer's disease amyloid propagation by a template-dependent dock-lock mechanism. Biochemistry 2000; 39 6288-6295.
39. Hasegawa K, Ono K, Yamada M, Naiki H. Kinetic modeling and determination of reaction constants of Alzheimer's β-amyloid fibril extension and dissociation using surface plasmon resonance. Biochemistry 2002; 41: 13 489-13 498.
40. Cantor CR, Schimmel PR. 1980; Biophysical Chemistry. W. H. Freeman and Co.: New York, 385-405.
41. Duysens LNM. The flattening of the absorption spectrum of suspensions, as compared to that of solutions. Biochim. Biophys. Acta 1956; 19: 1-12.
42. Miyazawa T. Perturbation treatment of the characteristic vibrations of polypeptide chains in various configurations. J. Chem. Phys. 1960; 32: 1647-1652.
43. Miyazawa T, Blout ER. The infrared spectra of polypeptides in various conformations: amide I and II bands. J. Am. Chem. Soc. 1961; 83: 712-719.
44. Hilbich C, Kisters-Woike B, Reed J, Masters CL, Beyreuter K. Aggregation and secondary structure of synthetic amyloid βA4 peptides of Alzheimer's disease. J. Mol. Biol. 1991; 218: 149-163.
45. 2O) solutions. II. Amide absorption bands of polypeptides and fibrous proteins in α-,β - and random coil conformations. Biopolymers 1990; 30: 1259-1271.
46. Choo L-P, Wetzel DL, Halliday WC, Jackson M, LeVine SM, Mantsch HH. In situ characterization of β-amyloid in Alzheimer's diseased tissue by synchrotron Fourier transform infrared microspectroscopy. Biophys. J. 1996; 71: 1672-1679.
47. Runnels LW, Scarlata SF. Theory and application of fluorescence homotransfer to melittin oligomerization. Biophys. J. 1995; 69: 1569-1583.
48. Wendt H, Berger C, Baici A, Thomas RM, Bosshard HR. Kinetics of folding of leucine zipper domains. Biochemistry 1995; 34: 4097-4107.
49. Terzi E, Hölzmann G, Seelig J. Self-association of β-amyloid peptide (1-40) in solution and binding to lipid membranes. J. Mol. Biol. 1995; 252: 633-642.
50. Matsuzaki K, Horikiri C. Interactions of amyloid β-peptide (1-40) with ganglioside-containing membranes. Biochemistry 1999; 38: 4137-4142.
51. Mason RP, Jacob RF, Walter MF, Mason PE, Avdulov NA, Chochina SV, Igbavboa U, Wood WG. Distribution and fluidizing action of soluble and aggregated amyloid β-peptide in rat synaptic plasma membranes. J. Biol. Chem. 1999; 274: 18 801-18 807.
52. Ji S-R, Wu Y, Sui S-F. Cholesterol is an important factor affecting the membrane insertion of β-amyloid peptide (Aβ1-40 , which may potentially inhibit the fibril formation. J. Biol. Chem. 2002; 277: 6273-6279.
53. Kremer JJ, Pallitto MM, Sklansky DJ, Murphy RM. Correlation of β-amyloid aggregate size and hydrophobicity with decreased bilayer fluidity of model membranes. Biochemistry 2000; 39: 10 309-10 318.
54. Avdulov NA, Chochina SV, Igbavboa U, Warden CS, Vassiliev AV, Wood WG. Lipid binding to amyloid β-peptide aggregates: Preferential binding of cholesterol as compared with phosphatidylcholine and fatty acids. J. Neurochem. 1997; 69: 1746-1752.
55. Fukuda H, Shimizu T, Nakajima M, Mori H, Shirasawa T. Synthesis, aggregation, and neurotoxicity of the Alzheimer's Aβ1-42 amyloid peptide and its isoaspartyl isomers. Bioorg. Med. Chem. Lett. 1999; 9: 953-956.
56. Maggio B, Cumar FA, Caputto R. Molecular behaviour of glycosphingolipids in interfaces. Possible participation in some properties of native membranes. Biochim. Biophys. Acta 1981; 650 69-87.
57. Shaikh SR, Dumaual AC, Jenski LJ, Stillwell W. Lipid phase separation in phospholipid bilayers and monolayers modeling the plasma membrane. Biochim. Biophys. Acta 2001; 1512: 317-328.
58. Hirai M, Iwase H, Hayakawa T, Koizumi M, Takahashi H. Determination of asymmetric structure of ganglioside-DPPC mixed vesicles using SANS, SAX, and DLS. Biophys. J. 2003; 85: 1600-1610.